指南与共识其他结缔组织病

抗磷脂综合征中血压与血脂管理对EULAR和欧洲心脏病学会建议的应用

Application of EULAR and European Society of Cardiology recommendations with regard to blood pressure and lipid management in antiphospholipid syndrome.
指南 / 共识 · RMD Open · 2023-01-01

该研究评估111例无既往动脉粥样硬化性心血管事件或糖尿病的抗磷脂综合征患者,按EULAR和ESC建议判断血压与血脂治疗资格。SCORE在超过50%的病例中低估高/极高实际心血管风险,采用疾病相关与心脏代谢特征的多模态风险评估可改善心血管风险管理。

要点

  • SCORE在超过50%的病例中低估高/极高实际心血管风险。
  • SCORE指导的血压/血脂治疗资格在高风险实际患者中分别为4.2%/12.6%,在极高风险实际患者中分别为10.5%/16.8%。
  • 采用糖尿病等高风险疾病所用的疾病相关与心脏代谢特征多模态风险评估可改善APS的心血管风险管理。

核心结论

  • 采用糖尿病等高风险疾病所用的疾病相关与心脏代谢特征进行多模态风险评估,可改善抗磷脂综合征的心血管风险管理。

研究设计与样本

  • 研究纳入111例无既往动脉粥样硬化性心血管事件或糖尿病的抗磷脂综合征患者。
  • 使用SCORE、改良SCORE、糖尿病等效风险分类器(DIME)及疾病相关分类器(血栓事件类型APSevents、抗磷脂抗体谱aPLprofile、调整后全球抗磷脂综合征心血管疾病评分)计算预测低-中、高和极高心血管风险。
  • 实际心血管风险按ESC指南确定,包括颈动脉/股动脉斑块存在与否。
  • 在SCORE预测低-中风险患者中,以实际风险分类为参考标准,用Matthews相关系数(MCC)和Cohen kappa分别检验血压或血脂治疗分类能力与一致性。

主要发现

  • SCORE在超过50%的病例中低估高/极高实际心血管风险。
  • SCORE指导的血压/血脂治疗资格在高风险实际患者中分别为4.2%/12.6%,在极高风险实际患者中分别为10.5%/16.8%,而5.3%的低-中风险实际病例符合降脂治疗资格。
  • 血压治疗方面,低-中风险和极高风险患者使用DIME的MCC较高(分别为0.33和0.32),高风险患者使用改良SCORE+APSevents的MCC=0.25。
  • 血压治疗资格一致性在高风险患者中使用DIME+APSevents或aPLprofile较好(kappa=0.51),在极高风险患者中使用DIME较好(kappa=0.31)。
  • 血脂治疗方面,低-中风险(MCC/kappa=0.43/0.41)和极高风险(MCC/kappa=0.30/0.30)患者使用SCORE(或改良SCORE)+APSevents的分类能力与资格一致性较强,高风险患者使用DIME+aPLprofile(MCC/kappa=0.50/0.50)较强。

关键数值与推荐

  • SCORE指导的血压治疗资格在高风险实际患者中为4.2%,在极高风险实际患者中为10.5%。
  • SCORE指导的血脂治疗资格在高风险实际患者中为12.6%,在极高风险实际患者中为16.8%,5.3%的低-中风险实际病例符合降脂治疗资格。
  • 血压治疗低-中风险使用DIME的MCC=0.33,极高风险使用DIME的MCC=0.32,高风险使用改良SCORE+APSevents的MCC=0.25。
  • 血压治疗资格一致性高风险使用DIME+APSevents或aPLprofile的kappa=0.51,极高风险使用DIME的kappa=0.31。
  • 血脂治疗低-中风险使用SCORE(或改良SCORE)+APSevents的MCC/kappa=0.43/0.41,极高风险为0.30/0.30,高风险使用DIME+aPLprofile为0.50/0.50。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To examine blood pressure (BP) and lipid treatment eligibility in antiphospholipid syndrome (APS) according to European Alliance of Associations for Rheumatology (EULAR) and European Society of Cardiology (ESC) recommendations. METHODS: Systematic Coronary Risk Evaluation (SCORE), modified-SCORE, diabetes mellitus (DM)-equivalent risk classifiers (DIME) and disease-related classifiers -type of thrombotic events (APSevents), antiphospholipid-antibody profile (aPLprofile) and adjusted Global APS Score for cardiovascular disease- were used to calculate predicted low-moderate, high and very-high cardiovascular risk (CVR) in 111 patients with APS without prior atherosclerotic cardiovascular events or DM. Actual CVR (AR) was determined according to ESC guidelines, including carotid/femoral plaque presence. In low-moderate SCORE-predicted risk patients, classification ability and agreement for BP or lipid treatment was tested with Matthews' correlation coefficient (MCC) and Cohen's kappa, respectively, using the AR classes as reference qualifiers. RESULTS: SCORE underestimated high/very-high-AR in >50% of cases. SCORE-guided BP/lipid treatment eligibility was 4.2%/12.6% for high, 10.5%/16.8% for very-high AR patients, while 5.3% of low-moderate AR cases were eligible for lipid-lowering therapy. For BP treatment, MCC was higher using DIME for low-moderate and very-high-risk (0.33 and 0.32, respectively), and using modified-SCORE+APSevents (MCC=0.25) for high-risk patients. Eligibility agreement was better with DIME+APSevents or aPLprofile (kappa=0.51) for high-risk, and DIME (kappa=0.31) for very-high-risk patients. For lipid treatment, both classification ability and eligibility agreement were stronger with SCORE (or modified-SCORE)+APSevents in low-moderate (MCC/kappa=0.43/0.41) and very-high risk (MCC/kappa=0.30/0.30), and with DIME+aPLprofile (MCC/kappa=0.50/0.50) in high-risk patients, respectively. CONCLUSION: Multimodal risk assessment including disease-related and cardiometabolic features used for high-risk diseases such as DM can improve CVR management in APS.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Drosos GC, Konstantonis G, Sfikakis PP, et al. Application of EULAR and European Society of Cardiology recommendations with regard to blood pressure and lipid management in antiphospholipid syndrome. RMD Open. 2023. PMID: 37558493. doi:10.1136/rmdopen-2023-003326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。